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Abstract. Active learning has shown to reduce the number of exper-
iments needed to obtain high-confidence drug-target predictions. How-
ever, in order to actually save experiments using active learning, it is
crucial to have a method to evaluate the quality of the current pre-
diction and decide when to stop the experimentation process. Only by
applying reliable stoping criteria to active learning, time and costs in the
experimental process can be actually saved. We compute active learning
traces on simulated drug-target matrices in order to learn a regression
model for the accuracy of the active learner. By analyzing the perfor-
mance of the regression model on simulated data, we design stopping
criteria for previously unseen experimental matrices. We demonstrate
on four previously characterized drug effect data sets that applying the
stopping criteria can result in upto 40% savings of the total experiments
for highly accurate predictions.
Keywords: active learning, drug-target prediction, simulation, matrix
factorization, regression
1 Introduction
A critical step in developing new therapeutics is frequently to conduct large
scale searches for potential drugs that can affect a desired target. Recently, it has
become clear that finding successful drugs also requires searching for the absence
of undesired effects on other targets. This need cannot be met by exhaustive
experimentation, but selective experimentation driven by machine learning (a
process referred to as active learning) may provide an alternative ([1]). The heart
of active learning is having good predictive models to guide experimentation.
Recent studies show that drug-target prediction algorithms can speed-up the
discovery of new drugs (e.g., [2–4, 16]).
⋆ This study was supported by BMBF e:BIO grant Microsystems, FKZ0316185. This
paper was selected for oral presentation at RECOMB 2015 and an abstract is pub-
lished in the conference proceedings.
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Current drug-target prediction methods are coarse grained over at most a
handful of ’campaigns’. In these, a classifier is trained with relatively large
amounts of training data resulting from exhaustive screening, and then verified
on a small test set. These data are generally identified manually, and limited to
human ’expert’ knowledge. This process is generally only performed once, or at
most a handful of times due to the expense of exhaustive screening over many
compounds. This procedure limits the generalization capability of the model and
does not allow for an optimal exploration of the drug-target interaction space.
Alternatively, active learning methods can be used to iteratively build a model
of drug-target interactions. Instead of relying on large training data sets, the
active learning procedure enlarges the training set stepwise, guided by the pre-
dictions on small, automatically-selected test sets. Thus time and costs are spent
on improving the general model rather than having the verification of a small
specific model that does not account for the large space of chemical compounds.
The general model has the potential to predict side-effects early on in the drug
design process, since a larger number of drugs are considered in the drug-target
prediction matrix. A critical point when using active learning to guide exper-
imentation is to decide when to stop, since the goal is to perform as few as
possible experiments in order to have the best model. The best stopping time is
reached when adding new experiments to the training set will not improve the
accuracy on the test set. The difficulty, of course, is that calculating the true
accuracy of the model requires all of the data. Therfore, reliable methods for
predicting the accuracy of the current model during an active learning cycle are
desired. Due to experimental cost and time restrictions, the best stopping time
might not be desirable, so it would be helpful to stop earlier when a predifined
confidence on the output of the model is reached.
Previous work in this area has generally addressed active learning methods
or drug-target prediction methods, but rerely both. For example, active learning
has been used to identify active compounds from a large pool of compounds
targeting a single molecule [5]. Active learning has also been applied in the con-
text of cancer research [24]. Several methods for drug-target prediction without
active learning have been proposed recently [15, 6, 27, 20, 19, 18, 17] and remain
an active area of research. The focus of this work is not to promote a particualar
drug-target prediction method, but to show using matrix factorization as an ex-
ample how drug-target prediction can be combined with active learning and lead
to reductions of experimentation cost. Initial results on applying active learning
for drug-target prediction on multiple drugs and multiple targets simultaneously
have been reported [7, 10], with and without requiring prior knowledge of drug or
target similarities. In [10] the benefits of active learning on a large dataset from
PubChem are reported, however without applying the stopping rule. In [7] an
intital method for predicting the accuracy of active learning traces is presented,
however it was not applied to the particular problem of drug-target pediction.
Several stopping rules for active learning have been considered in the past
[22, 23, 26], however there has been little analysis of which performs the best
in general. Four simple stopping criteria based on confidence estimation over
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the unlabeled data pool and the label consistency between neighboring train-
ing rounds of active learning have been presented [26]. Instead of using a single
criterion to stop, combining different stopping criteria in a feature vector de-
scribing the active learning trajectory has been proposed in [7]. The features of
trajectories on simulated data are used to train a regression function in order to
predict the accuracy of active learning algorithms on unseen simulated data. We
will follow this approach and adopt it to the binary drug-target prediction case.
The major goals of our active learning system are: (1) We want to have a fast
and reliable method to elucidate drug-target interactions. (2) Previous knowl-
edge on similarities between drugs and similarities between targets should be
included in the model, so that predictions for new drugs or targets (for which no
experiments are available) are possible. (3) The number of experiments required
to make confident predictions should be systematically reduced. (4) An efficient
stopping rule for ending the active learning process should be designed.
Previously, kernel-based matrix factorization ([11]) has been shown to pro-
vide good models of drug-target interactions ([8]). In the kernelized Bayesian
matrix factorization (KBMF) algorithm ([8, 9]), the drug-target interaction ma-
trix is factorized by projecting the drugs and the targets into a common sub-
space, where the projected drug matrix and the projected target matrix can be
multiplied in order to produce a prediction for the drug-target interaction ma-
trix. The entries of the prediction matrix are modeled using truncated normal
distributions. The projected drug matrix and target matrix are factored using
two different kernels: a drug specific kernel and a target specific kernel. A ker-
nel encodes the similarity between the drug and the target features. Thus prior
information can be easily inserted to the model. Furthermore, the knowledge of
the full interaction matrix is not needed in order to make predictions for new
drugs, which is not the case for previous methods (i.e. [6]).
The main contributions of this work are: (i) We use KBMF to construct a
powerful and practical active learning strategy for analyzing drug-target inter-
actions. (ii) We extend previous work [7] on estimating the accuracy of active
learning predictions to the KBMF case and show how it can be used to con-
struct a stopping rule for experimentation. (iii) We provide a proof of concept
through evaluation of the method on four data sets previously used for modeling
of drug-target interactions [12]. (iv) We show the superiority of the proposed
active learning approach compared to random choice of an equivalent number of
experiments.
2 Methods
Active Learning Framework
An active learning method is an iterative process composed of four components:
the initialization, the model, the active learning strategy and an accuracy mea-
sure for the predicted output in each step (Fig. 1). Most active learning papers
focus on the second and third components. The active learning framework starts
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Fig. 1: The major components of an active learning framework. The entries of
the matrix are color coded: label not known (light gray), interaction (black), no
interaction (white). At initialization a subset of known labels for the interactions
matrix and the drug and target kernels Kd and Kt are provided. In each round
of the active learning algorithm, the labels of the entire interaction matrix are
predicted and used to determine which labels to query next. In this figure, the
dark red values represent a high probability for a hit, whereas the dark blue
values represent a high probability for a miss.
with an initialization strategy which is followed by the generation of a model.
The model is used to make predictions, in our application drug-target interac-
tions are predicted. Interactions can be measured by performing an experiment,
i.e. a direct assay of drug-target interaction (e.g., in cell extracts). Based on
the predictions, an active learning strategy is applied to query new experiments
(labels) which will improve the model. We use batchwise learning, where a fixed
number of experiments is queried in each training round. Each training round
defines a time-point in the active learning process and is measured by the num-
ber of batches of experiments performed. For each time-point the accuracy of
the model is predicted. The process is stopped for example, if a certain budget
for performing experiments is reached or the predicted accuracy of the model is
high enough. We assume equal cost for each experiment.
Data Representation
We use interaction matrices Y ∈ {−1, 1}N×M to represent drug-target interac-
tions. We assume that the outcome of the experiment determines the ground
truth label l ∈ L = {−1, 1} for an interaction matrix entry. N ∈ N is the
number of drugs, M ∈ N is the number of targets. Knowledge of the interac-
tion between a drug d ∈ {1, 2, ..., N} and a target t ∈ {1, 2, ...,M} is ternary
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encoded in the experimental matrix X: +1 for an interaction, −1 for lack of
interaction, and 0 to denote experiments which have not yet been performed.
Hereby, the set of remaining experiments (unlabeled data) will be denoted by
X = {x = (d, t)|X(x) = 0}. Therefore, we consider a semi-supervised binary
labeling problem where the sign of the label indicates the interaction status
between a drug and a target.
Kernelized Bayesian Matrix Factorization (KBMF)
As described previously [8, 9], KBMF can be effectively applied to model drug-
target interactions. It approximates the interaction matrix by projecting the drug
kernel Kd ∈ R
N×N and the target kernel Kt ∈ R
M×M into a common subspace
of dimension R ∈ N such that the interaction matrix Y can be reconstructed
from the sign of its prediction matrix F ∈ RM×N :
Yˆ(d, t) =
{
1 if F(d, t) > 0
−1 else.
(1)
The prediction matrix F is a product of the projected kernel matrices:
F = ((Ad)
TKd)
T ((At)
TKt), (2)
where Ad ∈ R
N×R and At ∈ R
M×R are subspace transformation matrices
computed by the variational Bayes algorithm [8, 9] using the values of the ex-
perimental matrix X. The dimension R of the subspace is a free parameter;
we used the value of 20 previously determined to be optimal for these datasets
[9]. The entries of the kernel matrix Kd and Kt are a measure of the pairwise
similarities between drugs and targets respectively. The similarity matrices pro-
vided by Yamanishi et al. [12] and the KBMF implementation of semi-supervised
classification 1 provided by Goenen [9] were used.
Initialization and experiment selection
Our initialization strategy is to select a random column and one random exper-
iment from each row of the experimental matrix X.
Uncertainty sampling We use uncertainty sampling ([13]) to form a batch of
experiments {x1, .., xK} ∈ X by greedily choosing the K ∈ N experiments with
the greatest uncertainty function U ([26]):
U(x) = −
∑
l∈L
P (l|x)logP (l|x). (3)
For the KBMF case the posterior probability is computed by the sigmoid
function from the predicted interactions:
P (l = 1|x) =
1
1 + exp(−F(x))
, (4)
1 http://research.ics.aalto.fi/mi/software/kbmf/
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and P (l = −1|x) = 1− P (l = 1|x) for no interaction respectively.
Stopping Rule
In order to stop the active learning process, a method is needed to predict the
accuracy of the model for a given time-point along with the confidence of that
prediction. As proposed previously in [7], the accuracy of a model at a given
point in an active learning process can be predicted using a regression function
trained for other, similar experimental spaces. The fully observed drug-target
space is characterized by two measures, uniqueness (u) and responsiveness (r)
[7] defined by:
r =
1
N ·M
∑
d,t,Y (d,t)=1
Y(d, t) (5)
u =
uRows(Y) + uColumns(Y)
N +M
, (6)
where uRows(.) and uColumns compute the number of unique rows and
unique columns of a matrix.
The uniqueness and responsiveness are values in the range [0, 1] and charac-
terize the interaction matrix. Responsiveness measures the percentage of inter-
actions in the matrix. Uniqueness is a measure of independence of the rows and
columns in the matrix. The higher the value for uniqueness is, the more difficult
it is to make predictions.
These two measures have two purposes: (1) They are used to compute fea-
tures for a time-step in our current active learning process. (2) They can be used
to generate simulation data having similar properties to the measured experi-
mental data.
Each time-point ti is described by a vector of 13 features fti ∈ R
13, defined
as:
– f(1), f(2): average observed responsiveness across columns (respectively rows)
– f(3), f(4): average predicted responsiveness across columns (respectively
rows)
– f(5): average difference in predictions from last prediction for current time-
point (ti)
– f(6): average difference in predictions from last prediction for previous time-
point (ti−1)
– f(7): fraction of predictions at ti−1 observed as responsive (l = 1) at ti
– f(8), .., f(10): minimum, maximum and mean number of experiments that
have been performed for any drug
– f(11), .., f(13): minimum, maximum and mean number of experiments that
have been performed for any target
These features are normalized to the range [0..1] and are further extended
by computing the square root of their pairwise products.
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To learn the accuracy predictor via simulation data, interaction matrices of
size 50×50 were randomly sampled in the grid of uniqueness and responsiveness
parameters 5%, 10%, . . . , 95%. For each interaction matrix we derived ’perfect’
Gaussian similarity kernels Kd,Kt by pairwise distances of the column-space
and row-space, respectively. These were disrupted by forcing 0%, 5%, 10% of the
kernel entries to the value 1 and regularized to ensure positive semidefiniteness.
Features computed from trajectories of the uncertainty sampling active learner
on these data were collected; for each trajectory we also measured the accuracy
of prediction against the ground truth. A linear model of these features against
adjusted accuracies (accuracy above the fraction of experiments performed so
far) was fitted by lasso regression ([14]). The lasso regularization parameter was
chosen by 11-fold cross validation under squared loss, with holdout granularity
at the level of trajectories. To make accuracy predictions from adjusted accuracy
predictions, we added the fraction of experiments performed so far.
3 Results
For validation of our method, experiments are performed on four data sets ex-
tracted from the KEGG BRITE ([21]), BRENDA [25] , SuperTarget [28] and
DrugBank [29] databases, previously described by Yamanishi et al [12] 2. The
data set consists of four drug-target interaction matrices: Nuclear Receptor,
GPCR, Ion Channel and Enzyme.
Comparison of active and random learning strategies
In order to evaluate the efficiency of active learning methods, we compared the
uncertainty sampling strategy with random choice of experiments in each time-
step. On all four data sets the active learning strategy outperformed the random
strategy (Fig. 2). On the GPCR and the Ion Channel dataset the active learning
strategy using uncertainty sampling reaches 99% accuracy 5-6 times faster than
the random strategy.
Predicting the accuracy of the model
As discussed in the introduction, in practice we require a mechanism to decide
when to stop experimentation. It is not enough to have a good active learning
method without the possibility to evaluate the accuracy of the whole model apart
from acquiring all the data. Therefore we have simulated interaction matrices
with uniqueness, responsiveness in the range [0.05..0.95] and kernel noise in the
range [0..0.1]. We then performed active learning simulations using our KBMF
model and uncertainty sampling and learned a regression function for the pre-
dicted accuracy. The results of applying the regression function to the computed
features at each time point are shown in red in Fig. 3 for the four data sets. On
2 http://web.kuicr.kyoto-u.ac.jp/supp/yoshi/drugtarget/
8 Temerinac-Ott, M., Naik, A.W., Murphy, R.F.
(a) Nuclear Receptor (b) GPCR
(c) Ion Channel (d) Enzyme
Fig. 2: Comparison of random sampling (green) to uncertainty sampling (black)
on the four data sets. The solid and the dotted line represent respectively the
mean and the standard deviation of 5 random initializations. For random sam-
pling five random runs were performed for each initialization.
all four data sets, the predicted accuracy of 90% guarantees the true accuracy
to be at least 90%, and the predicted accuracies are a reasonable lower estimate
for the true accuracy.
Learning the stopping rule
Statistics on the performance of the accuracy predictor in simulations can be
used to design a stopping rule [7]. We adopt this method to determine a thresh-
old for stopping the active learning procedure. The simulated data is used to
assess the probability that the true accuracy is greater than or equal to the
predicted accuracy using 11-fold cross-validation. We count for each predicted
accuracy value how often the condition was fulfilled and divide it by the total
occurrence of this predicted value (Fig. 4). As expected, a low predicted accu-
racy with a value below 0.5 will have a high probability to be measured higher
in the actual experiment. Predicted values below 0.5 are not of interest, since
the predicted value is too low. In the beginning of the active learning procedure
a small amount of data is available, so it is hard to make good predictions about
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(a) Nuclear Receptor (b) GPCR
(c) Ion Channel (d) Enzyme
Fig. 3: The true accuracy (black) and the predicted accuracy (red) are shown for
the four data sets.
the accuracy of the method. However, the more data is gathered in the active
learning procedure, the more confident the predictor gets, reaching a peak for
predicting the accuracy of 0.8 and higher for 65% of the cases. For very high
accuracies (> 0.95), the chance that the actual accuracy exceeds the prediction
naturally drops drastically. From Fig. 4 the best threshold to stop lies in the
range 0.8 to 0.9. Since higher accuracy values are more desirable, our stopping
rule was to terminate the active learning procedure, when the predicted accuracy
is 0.9.
Applying the stopping rule
In the original KBMF paper ([8]), the KBMF classifier was evaluated by 5-fold
five cross validation using 80% of drugs for training and 20% of drugs for testing.
We wanted to test if a matching accuracy on the test set could be reached by
choosing actively a reduced number of experiments for training. In other words,
assuming that we get to perform selected experiments drawn from a given set,
use them to train a model, and make predictions for a held out set (for which
experiments are not possible), can we get an accurate model without doing all
experiments? For this purpose our active learning strategy was modified. We use
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Fig. 4: The probability that a predicted accuracy is below or equal to the true
accuracy is plotted against the threshold.
Table 1: Average AUC on hold out data and percentage of experiments after
applying our stopping rule. The average AUC obtained on held out data using
80% of the data for training [8] is compared with the average AUC obtained
by training with only the listed percentage of experiments obtained by applying
the stopping rule. The percentage of experiments can be halved by using the
proposed stopping rule.
Goenen results With stopping rule
Dataset AUC (%) AUC(%) experiments (%)
Nuclear Receptor 82.4 81.7 52.9
GPCR 85.7 81.6 39.3
Ion Channel 79.9 83.8 44.2
Enzyme 83.2 77.8 29.7
1% of drugs as the batch size and select in each run the drugs which the classifier
is the most uncertain about. For uncertainty sampling using the predictions of
the KBMF classifier, this means that drugs with the maximal mean uncertainty
across targets are selected.
Instead of using all 80% of drugs for training ([8]), we use the predicted
accuracy on the training data to stop acquisition. When the predicted accuracy
on the training set reaches a threshold, the active learning process is stopped
and the AUC value on the test set (the 20% of the drugs which were held out)
is reported. The average results after 5-fold five cross validation are reported in
Table 1. By using the stopping-rule on all four data sets, only half of the drugs
were needed for training to reach a similar AUC value to that when using all
80% of the drugs for training.
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Table 2: Average difference between the BST point and the stopping point chosen
by various stopping rules, over all evaluation data sets. OU=Overall Average Un-
certainty, MEE=Minimum Expected Error PA=Predicted Accuracy. The value
in the brackets denotes the threshold. The smaller the difference ∆ave value is,
the better the stopping criterion is.
Methods OU(0.12) OU(0.09) OU(0.06) OU(0.03) OU(adapted)
∆ave(%) 40.1 (± 12.2) 33.8 (± 17.8) 40.1 (± 21.3) 50.9 (± 5.4) 28.2 (± 29.1)
Methods MEE(0.12) MEE(0.09) MEE(0.06) MEE(0.03) MEE(adapted)
∆ave(%) 40.1 (± 11.7) 38.3 (± 12.7) 36.1 (± 13.4) 40.6 (± 12.1) 30.3 (± 12.6)
Methods PA(0.85) PA(0.9) PA(0.95)
∆ave(%) 32.8 (± 8.8) 13.7 (± 11.3) 22.1 (± 15.4)
Comparison Of Stopping Rules
We compared the stopping criteria overall uncertainty (OU) and minimum ex-
pected error (MEE) with a fixed threshold as well as an adapted threshold based
on label consistency as described [26] with the stopping method based on pre-
dicted accuracy [7] in Table 2. As in [26] we use the absolute difference of the
percentage of experiments completed at the stopping time-point to the percent-
age of experiments completed at the best stopping time (BST) averaged over
four data sets (∆ave) to evaluate different stopping criteria. In [26] the BST is
defined as the time-point, when the classifier first reaches the highest perfor-
mance. The predicted accuracy (PA) method with threshold 0.9 produces the
smallest average error to the BST. Both MEE and OU perform two to three
times worse than the PA method, even with the adaptive threshold method.
The fixed threshold for OU and MEE fails on average, because each of the four
data sets has a different optimal threshold for OU and MEE. The maximum
uncertainty (MU) and the selected accuracy (SA) stopping criteria [26] could
not be applied, since those curves are not continuous on these data sets.
4 Conclusions and Discussion
We have presented an active learning method for prediction of drug-target in-
teractions based on kernelized matrix factorization. Building on prior work [8],
our model can efficiently leverage prior information through kernels to achieve
high predictive accuracy. We have furthermore shown that our method can sig-
nificantly improve the prediction task for drug-target interactions when only a
limited number of experiments can be performed. For three real-world data sets
with high uniqueness values, the active learning strategy achieves 99% accuracy
with 2-3 times fewer experiments than a random sampling strategy. It is impor-
tant to note that our goal was not to choose the best possible matrix completion
method for these specific datasets, but to show that a good method can be used
as a basis for active learning to dramatically reduce further experimentation.
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Please note, that the presented framework is not limited to KBMF only. Any
other model for drug target prediction could be apllied that produces outputs
for drug-target scores which can be converted into probabilities. Furthermore
the selection strategy uncertainty sampling could be replaced by other active
learning strategies (i.e. diversity sampling) to learn new traces on simulated data.
The active learning features could be improved by feature selection methods.
For a practitioner to realize these advantages, we have provided a method for
estimating the accuracy of an actively learned model using only experimental
results already collected; this estimated accuracy is generally a lower bound of
the true accuracy of the model. We have shown that this method, calibrated
from simulation data, accurately assesses the active learner performance on our
real-world data. We have also shown that by applying a stopping rule learned on
the simulated data, only half of the experiments are needed to achieve similar
accuracies on holdout data. We conclude that active learning driven experimen-
tation is a practical solution to large experimental problems in which time or
expense make exhaustive experimentation undesirable.
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